Overview
Stock Info
Quarterlies
New Releases
Events
Stay Updated
Corporate Presentation
Analyst Coverage
Palisade Bio is followed by the analysts listed here. Please note that any opinions, estimates or forecasts regarding Palisade Bio’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Palisade Bio or its management. Palisade Bio does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Company
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s Disease (FSCD).
Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).